This company is no longer active
Diffusion Pharmaceuticals Management
Management criteria checks 2/4
Key information
Bob Cobuzzi
Chief executive officer
US$783.4k
Total compensation
| CEO salary percentage | 52.3% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.4yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$783k | US$410k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$1m | US$129k | -US$16m |
Compensation vs Market: Bob's total compensation ($USD783.35K) is above average for companies of similar size in the German market ($USD435.71K).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Cobuzzi (57 yo)
2.4yrs
Tenure
US$783,352
Compensation
Dr. Robert J. Cobuzzi, Jr., also known as Bob, Ph D., serves as an Independent Director at Diffusion Pharmaceuticals Inc. since January 7, 2020 and serves as its President & Chief Executive Officer since S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.4yrs | US$783.35k | 0.079% € 9.9k | |
| Chief Financial Officer | 4.4yrs | US$535.52k | 0% € 0 | |
| General Counsel & Corporate Secretary | 2.4yrs | US$404.61k | 0.020% € 2.5k | |
| Chief Medical Officer | 2.3yrs | US$625.99k | 0.029% € 3.7k | |
| Senior Medical Advisor | 10.4yrs | no data | no data | |
| Senior Director & Head of Quality Assurance | 1.9yrs | no data | no data | |
| Senior Director & Head of CMC | 1.4yrs | no data | no data | |
| Chief Regulatory Officer | less than a year | no data | no data | |
| Vice President of Clinical Operations | 6.4yrs | no data | no data | |
| Senior Consultant for Manufacturing | no data | no data | no data | |
| Senior Consultant - Regulatory Affairs | no data | no data | no data |
2.4yrs
Average Tenure
52yo
Average Age
Experienced Management: DP81's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$783.35k | 0.079% € 9.9k | |
| Independent Director | 7.1yrs | US$118.50k | 0.0016% € 202.8 | |
| Independent Chairman | 2.4yrs | US$124.46k | 0.049% € 6.1k | |
| Lead Independent Director | 7.1yrs | US$115.00k | 0.053% € 6.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.1yrs | US$114.70k | 0.0035% € 441.8 | |
| Member of Scientific Advisory Board | 1yr | no data | no data | |
| Member of Scientific Advisory Board | 1yr | no data | no data | |
| Independent Director | 1.7yrs | US$189.51k | 0% € 0 | |
| Member of Scientific Advisory Board | 1yr | no data | no data | |
| Member of Scientific Advisory Board | 1yr | no data | no data | |
| Member of Scientific Advisory Board | 1yr | no data | no data |
1.7yrs
Average Tenure
58.5yo
Average Age
Experienced Board: DP81's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/13 22:24 |
| End of Day Share Price | 2022/11/16 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diffusion Pharmaceuticals Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| David Bautz | Zacks Investment Research Inc. |
| David Bautz | Zacks Small-Cap Research |